Immune-Onc partners with University of Texas to develop novel cancer immunotherapy

Palo Alto, USA biotech startup Immune-Onc Therapeutics, focused on advancing promising immuno-oncology therapeutics, has entered into an exclusive license and collaboration agreement with The University of Texas Health Science Center at Houston (UTHealth) and The University of Texas Southwestern Medical Center (UTSW), two member institutions of The University of Texas System (UT System).

Under the terms of the license agreement, Immune-Onc will acquire the exclusive global rights to develop and commercialize novel biotherapeutics with applications in cancer immunotherapy and other diseases. In addition, Immune-Onc has entered into a multi-year research collaboration with UTHealth and UTSW to discover and develop a new generation of biotherapeutics that modulate the immune system.

This collaboration will leverage the Cancer Prevention & Research Institute of Texas (CPRIT) Therapeutic Monoclonal Antibody Lead Optimization and Development Core Facility at UTHealth to advance lead antibodies from academic laboratories, and will utilize the preclinical and clinical drug development expertise of Immune-Onc to move them to clinical trials and eventually to eligible patients.